ArticleCancer immunology, immunotherapy : CII2013
Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
Article in Cancer immunology, immunotherapy : CII, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 22 citations in OpenAlex.
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- NK cells propagate T cell immunity following in situ tumor vaccination.Cell reports · 2023Article
- Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.Radiation research · 2021Article
- Review
- Radiation Augments the Local Anti-Tumor Effect ofFrontiers in immunology · 2021Article
- In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.Journal for immunotherapy of cancer · 2020Article
- Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.Biologics : targets & therapy · 2019Review
- Tumor-Associated Macrophages as Target for Antitumor Therapy.Archivum immunologiae et therapiae experimentalis · 2018Review
- The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.Cancer immunology, immunotherapy : CII · 2018Article
- Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.Frontiers in immunology · 2018Review
- Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Article
- Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.International journal of molecular sciences · 2017Review
- Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Immunotherapy · 2016Review
- In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.Cancer research · 2016Article
- Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct.Journal of materials chemistry. B · 2016Article
- Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.Seminars in oncology · 2015Review
- Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Oncology reports · 2014Review
- Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma.International journal of nanomedicine · 2014Article
- Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.Oncoimmunology · 2013Review
- Tumor-Associated Glycans and Immune Surveillance.Vaccines · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Targeted monoclonal antibodies (mAb) can be used therapeutically for tumors with identifiable antigens such as disialoganglioside GD2, expressed on neuroblastoma and melanoma tumors. Anti-GD2 mAbs (αGD2) can provide clinical benefit in patients with neuroblastoma. An important mechanism of mAb therapy is antibody-dependent cellular cytotoxicity (ADCC). Combinatorial therapeutic strategies can dramatically increase the anti-tumor response elicited by mAbs. We combined a novel αGD2 mAb, hu14.18K322A, with an immunostimulatory regimen of agonist CD40 mAb and class B CpG-ODN 1826 (CpG). Combination immunotherapy was more effective than the single therapeutic components in a syngeneic model of GD2-expressing B16 melanoma with minimal tumor burden. NK cell depletion in B6 mice showed that NK cells were required for the anti-tumor effect; however, anti-tumor responses were also observed in tumor-bearing SCID/beige mice. Thus, NK cell cytotoxicity did not appear to be essential. Peritoneal macrophages from anti-CD40 + CpG-treated mice inhibited tumor cells in vitro in an hu14.18K322A antibody-dependent manner. These data highlight the importance of myeloid cells as potential effectors in immunotherapy regimens utilizing tumor-specific mAb and suggest that further studies are needed to investigate the therapeutic potential of activated myeloid cells and their interaction with NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.